The price from Blinkhealth in U.S.A
1.Sovaldi(Sofosbuvir)：$29,246.19 (28 Tablets400 mg )
2.Harvoni(Ledipasvir/Sofosbuvir )：$32,901.18 (28 Tablets90-400 mg)
**3.Epclusa(Sofosbuvir/Velpatasvir) *：$27,888.62 (30 Tablets400-100 mg)
Above is a hepatitis C treatment drug launched by Gilead Sciences in the United States, the first generation to the third generation.
Have you noticed the price change?
In fact, Epclusa is not just about lower retail prices.
1）Age criteria for drug use in patients
1.Sovaldi(Sofosbuvir)：Over 12 years old
2.Harvoni(Ledipasvir/Sofosbuvir )：Over 12 years old
3.Epclusa(Sofosbuvir/Velpatasvir) ：Over 18 years old
Epclusa currently targets only adult patients, which is a disadvantage.
2）Hepatitis C genotyping
1.Sovaldi(Sofosbuvir)： genotype-1, -2, -3, -4
2.Harvoni(Ledipasvir/Sofosbuvir )： genotype-1, -4, -5, -6
3.Epclusa(Sofosbuvir/Velpatasvir) ：genotype-1, -2, -3, -4, -5, -6
Epclusa has a wider range of indications.
This means that the drug can also be used in many developing countries that do not have genotyping tests.
3）Medication cycle
1.Sovaldi(Sofosbuvir)： Usually 12 weeks, the longest treatment cycle is 24 weeks.
2.Harvoni(Ledipasvir/Sofosbuvir )： Usually 12 weeks, the longest treatment cycle is 24 weeks.
3.Epclusa(Sofosbuvir/Velpatasvir) ：It only takes 12 weeks.
Epclusa has shorter treatment cycles。
This means that patients can buy relatively few drugs to cure hepatitis C.
And now,Epclusa has lower retail pricing.We believe that all this is for Epclusa to be applied worldwide.
We anticipate that Epclusa will be cheaper and cheaper until it becomes the most basic treatment for hepatitis C patients worldwide.
Humans are protected from hepatitis C globally, thanks to Gilead Sciences
For more detailed drug use differences, please refer to What are the differences between Sovaldi/Harvoni/Epclusa？